<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256254</url>
  </required_header>
  <id_info>
    <org_study_id>2014-647</org_study_id>
    <nct_id>NCT02256254</nct_id>
  </id_info>
  <brief_title>SIMOX - Induction of Oxidative Stress</brief_title>
  <acronym>SIMOX</acronym>
  <official_title>SIMOX - A Randomized, Double-blinded, Placebo Controlled Study of Simvastatins Possible Effect on Oxidative Stress on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinisk Biokemisk Afdeling</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinisk farmakologisk Afdeling</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sektion for Biomedicin Institut for Veterinær Patobiologi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate if use of simvastatin is associated with the level
      of oxidative stress in humans. The association is examined by comparing changes in oxidative
      stress in a group treated with simvastatin with the change in a placebo group. The study is a
      randomized-based, double-blinded placebo-controlled study. Each treatment group consists of
      20 healthy male volunteers who consume simvastatin or placebo over 14 days. The induction of
      oxidative stress is measured by 8-oxoguanosine and 8- oxodeoxyguanosine, isolated from urine.
      A t-test will be performed to compare drug treatment with placebo. The results will be
      published.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion of 8-oxoguanosine (nmol/24h)</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretion of 8-oxodeoxyguanosine (nmol/24h)</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin C</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin E</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopterin</measure>
    <time_frame>Change from Baseline after fourteen days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Simvastatin capsules of 20 mg every evening for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo capsules every evening for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>2 Simvastatin capsules of 20 mg every evening for 14 days</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo capsules every evening for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian

          -  healthy men

          -  18-50 years

          -  BMI: 18-30

        Exclusion Criteria:

          -  Total cholesterol less than 3 mmol/L

          -  Use of natural and herbal medicines that is affected/affects simvastatin:

        anion exchangers, amiodarone, amlodipine, ciclosporin, clarithromycin, colchicine, danazol,
        diltiazem, erythromycin, fibrates, fluconazole, fusidin acid, grape fruit juice, HIV
        protease inhibitors, itraconazole, ketoconazole, nefazodone, niacin, posaconazole,
        rifampicin, telithromycin, verapamil, vitamin K-antagonists, voriconazole

          -  following diseases: a Coronary vascular disease b Renal insufficiency c Hepatic
             insufficiency d heart failure e Previous heart arrythmia f Hypokalaemia g Low blood
             pressure h hyperthyroidism i muscular toxicity j galactose intolerants k Lapp Lactase
             deficiency l Glucose/galactose‐malabsorption m Psychiatric disorder

          -  allergies towards any of the tested medicine

          -  intake of narcotics within 2 months prior to trial

          -  intake of supplements within 2 months prior to trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Enghusen Poulsen, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department head</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henrik Enghusen Poulsen</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <keyword>Oxidative stress</keyword>
  <keyword>Simvastatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

